Saturday - April 11, 2026

Natural Killer (NK)-Cell Lymphoma Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Natural Killer Cell Therapies Pipeline Insight 2025” report provides comprehensive insights about 100+ companies and 140+ pipeline drugs in Natural Killer Cell Therapies pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also … Continue reading

Clear Cell Sarcoma Pipeline Appears Robust With 6+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Clear Cell Sarcoma Pipeline Insight 2025” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Clear Cell Sarcoma pipeline landscape. It covers the Clear Cell Sarcoma pipeline drug profiles, including clinical and nonclinical stage products. It … Continue reading

PD-1+ NSCLC Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Pipeline Insight 2025” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical … Continue reading